Highlights Kinarus Therapeutics Holding AG

Equities

CURE

CH0009115129

Market Closed - Swiss Exchange Other stock markets 10:38:47 2024-04-26 am EDT			5-day change	1st Jan Change
15 ^CHF	-6.99%		-6.99%	+737.05%

Apr. 26	Kinarus Therapeutics Completes Merger with Unit, Rebrands as Curatis	MT
Apr. 25	Curatis AG completed the acquisition of Kinarus Therapeutics Holding AG for CHF 18.3 million in a reverse merger transaction.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kinarus Therapeutics Completes Merger with Unit, Rebrands as Curatis	Apr. 26	MT
Reverse Split: 1 of 4480	Apr. 25	FA
Curatis AG completed the acquisition of Kinarus Therapeutics Holding AG for CHF 18.3 million in a reverse merger transaction.	Apr. 24	CI
Swiss Exchange Regulator Drops Inquiry Into Kinarus Therapeutics	Mar. 28	MT
Kinarus Therapeutics Receives Swiss Court Approval for Revocation of Bankruptcy	Feb. 06	MT
Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG in a reverse merger transaction.	Jan. 28	CI
Kinarus Therapeutics' H1 Loss Widens	23-08-31	MT
Kinarus Therapeutics Holding AG Signs Licensing Agreement to Extend Cash for Operations	23-08-25	CI
Kinarus Therapeutics Posts Higher FY22 Attributable Loss	23-05-31	MT
SIX Exchange Probes Kinarus Therapeutics Over Potential Disclosure Violation	23-05-19	MT
Kinarus Therapeutics Secures Extension for FY22 Results Publication	23-04-28	MT
Kinarus Therapeutics Provides Update on Phase 2 Kinfast Covid-19 Clinical Trial Progress	23-02-21	CI
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan	23-01-17	CI
Kinarus Therapeutics Secures US Patent for Eye Drug KIN001	22-11-22	MT
Kinarus Therapeutics, Great Health Explore Partnerships for Mid-stage Trial of Eye, Lung Disease Drug in China	22-11-16	MT
Kinarus Therapeutics Swings to H1 Loss Amid Expenses Related to Investigational COVID-19 Drug Trial	22-08-31	MT
Kinarus Therapeutics' Drug Combination Shows Strong Antiviral Efficacy Against All COVID-19 Variants	22-06-20	MT
Swiss Biopharmaceutical Group Perfect Changes Name To Kinarus Therapeutics	22-06-10	MT
Kinarus Therapeutics Starts Trading on SIX Swiss Exchange Upon Perfect Holding Merger Completion	22-06-03	MT
Kinarus AG completed the acquisition of Perfect Holding SA, in a reverse merger transaction.	22-06-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kinarus Therapeutics Holding AG

Equities

CURE

CH0009115129

Highlights

Filters